Brief: Data Supporting Use Of Predictive Enrichment Markers For Lumos Pharma’S Lum-201 Therapy In Clinical Trials
04/03/2021 14:05
March 4 (Reuters) - Lumos Pharma Inc LUMO.O :
* DATA SUPPORTING USE OF PREDICTIVE ENRICHMENT MARKERS FOR
LUMOS
PHARMA’S LUM-201 THERAPY IN CLINICAL TRIALS FOR MODERATE PGHD
PUBLISHED IN JOURNAL OF THE ENDOCRINE SOCIETY
Source text for Eikon: ID:nGNX48KSLz
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)